OCUL Stock: Price, Earnings History and SEC Filings
Ocular Therapeutix, Inc. (OCUL) last traded at $6.97, down 4.65% on the latest session and down 9.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.35 against an analyst estimate of $-0.40, a beat of 12.5%.
$6.97 -4.65%
1 month-9.13%
52-week high$16.44
52-week low$6.00
Volume2.63M
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
OCUL earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 3, 2026 | $-0.35 | $-0.40 | +12.50% |
| Mar 2026 | May 5, 2026 | $-0.41 | $-0.32 | -28.12% |
| Dec 2025 | Feb 5, 2026 | $-0.29 | $-0.33 | +12.12% |
| Sep 2025 | Nov 4, 2025 | $-0.37 | $-0.39 | +5.13% |
OCUL beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for OCUL
SEC filing data is not available right now. You can search for OCUL on SEC EDGAR.
OCUL news
- Ocular Therapeutix™ to Participate in November Investor and Scientific ConferencesOct 29, 2026 · finance.yahoo.com
- Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 WinOct 20, 2026 · marketbeat.com
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (OCUL) is a US-listed public company on Nasdaq.